title: ▼Relvar Ellipta for COPD.
abstract: ▼Relvar Ellipta 92 μg/22 μg (GSK) is a dry powder inhaler that contains a corticosteroid (fluticasone furoate) and a long-acting beta2 agonist (vilanterol trifenatate).1 Neither ingredient is currently marketed as a single-ingredient inhalation product, although fluticasone furoate is available as a nasal spray for the treatment of allergic rhinitis. Relvar Ellipta 92 μg/22 μg is licensed for once-daily use as maintenance therapy for chronic obstructive pulmonary disease (COPD) and asthma. In this article we consider the evidence for its use in the management of patients with COPD. An article in a future issue will review its use in the management of patients with asthma.
mesh_terms: D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use*; D001592:Benzyl Alcohols / Q000008:administration & dosage / Q000627:therapeutic use*; D002722:Chlorobenzenes / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D058995:Dry Powder Inhalers; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000730:Androstadienes; D001592:Benzyl Alcohols; D002722:Chlorobenzenes; D004338:Drug Combinations; D005938:Glucocorticoids; C550468:vilanterol; C523187:fluticasone furoate